<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871921</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00015937</org_study_id>
    <secondary_id>R56AG056102</secondary_id>
    <secondary_id>R01AG051628</secondary_id>
    <secondary_id>R01AG056102</secondary_id>
    <nct_id>NCT02871921</nct_id>
  </id_info>
  <brief_title>Internet-based Conversational Engagement Clinical Trial</brief_title>
  <acronym>I-CONECT</acronym>
  <official_title>Internet-based Conversational Engagement Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to randomize 320 (160 Caucasian, 160 African American) socially isolated&#xD;
      adults 75+ years old (50:50 split between those with normal cognition and mild cognitive&#xD;
      impairment (MCI)) recruited from the community to either the Video Chat Group or the Control&#xD;
      Group. The participants in the Video Chat Group will receive a computer and internet service&#xD;
      for the duration of the study, which they will use to video chat with study staff for 30&#xD;
      minutes/day 4x/week for 6 months (high dose), and then 2x/week for an additional 6 months&#xD;
      (maintenance dose). The efficacy examination of the maintenance dose is limited to an&#xD;
      exploratory aim. Both intervention and control groups will have a brief (about 10 minutes)&#xD;
      telephone check-in with study staff once per week. In-home testing will occur at Baseline and&#xD;
      6 months. A sub-sample of participants** will be assessed at 12 months (exploratory) after&#xD;
      additional 6 months of maintenance dose. All participants at OHSU will have their medication&#xD;
      compliance tracked using an electronic medication monitoring device and participants at both&#xD;
      OHSU and UM will have MRIs at Baseline and 6 months, if they are able to safely receive MRIs.&#xD;
      Participants at both sites will contribute saliva for genetic testing (optional consent), and&#xD;
      all video chat and neuropsychological assessment sessions will be recorded for speech and&#xD;
      language analysis (consent required for participation).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      **Due to COVID-19 pandemic and resultant research hiatus and the subsequent changes in&#xD;
      assessment modality from in-person to telephone (T-COG) assessments, M12 (Months 12)&#xD;
      assessments are conducted only among those who completed M12 assessments before March, 18,&#xD;
      2020.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">August 31, 2021</completion_date>
  <primary_completion_date type="Actual">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Study assessors will be blinded to the subject study arm assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Intervention Efficacy for High Dose : Global Cognitive Function</measure>
    <time_frame>Change from baseline to month 6</time_frame>
    <description>Global cognitive function measured by the Montreal Cognitive Assessment total score (MoCA total score). Montreal Cognitive Assessment is a neuropsychological test. Total score ranges from 0 to 30. Higher scores indicate better cognitive function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intervention Efficacy for High Dose: Language-based executive function</measure>
    <time_frame>Change from baseline to month 6</time_frame>
    <description>Cognitive function in language-based executive function measured by Verbal Fluency Animal test. Verbal fluency Animals test is a neuropsychological test. In the test, participants have to produce as many words as possible from a category of animals within 60 seconds. Total score ranges from 0 to 70. Higher scores indicate better cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervention Efficacy for High Dose: learning function</measure>
    <time_frame>Change from baseline to month 6</time_frame>
    <description>Cognitive function in a learning domain (immediate recall) measured by Craft Story Immediate Recall test (paraphrase scoring). Craft Story Immediate Recall test (paraphrase scoring) is a neuropsychological test. Total score ranges from 0 to 25. Higher scores indicate better cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervention Efficacy for High Dose: Memory function</measure>
    <time_frame>Change from baseline to month 6</time_frame>
    <description>Cognitive function in a memory domain measured by Craft Story Delayed Recall test scores (paraphrase scoring). Craft Story Delayed Recall test (paraphrase scoring) is a neuropsychological test. Total score ranges from 0 to 25. Higher scores indicate better cognitive function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervention Efficacy for High Dose: objectively assessed IADL (Instrumental Activities of Daily Living) functions</measure>
    <time_frame>Change from baseline to month 6</time_frame>
    <description>The Revised Observational Tasks of Daily Living (OTDL-R) includes a total of 9 IADL tasks (28 items, maximum score = 28), three each in the domains of medication use, telephone use, and financial management. The higher score indicates better function.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory Analysis: Cognitive Tests by NIH Toolbox</measure>
    <time_frame>Change from baseline to month 6</time_frame>
    <description>Examine the intervention's efficacy on the same cognitive domains (executive and memory functions) using the NIH-Toolbox for cross-validation of domain responsiveness of our intervention.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Analysis: Emotional battery by NIH Toolbox</measure>
    <time_frame>Change from month 6 to month 12</time_frame>
    <description>Examine the intervention's efficacy on psychological well-being using the NIH-Toolbox emotional battery test scores</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Analysis: structural and resting state functional MRI</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Examine region specific structural and functional pre-post changes in brain using magnetic resonance imaging (MRI, fMRI)</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Analysis: Speech and Language Characteristics</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Examine whether the intervention could lead to changes in speech and language characteristics over time by analyzing recorded video chats in the experimental group</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Analysis: Speech and Language Characteristics</measure>
    <time_frame>Change from baseline at 12 months</time_frame>
    <description>Examine whether the intervention could lead to changes in speech and language characteristics over time by analyzing recorded video chats in the experimental group</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Analysis. Intervention Efficacy for High Dose: Medication adherence measured by electronic pill box (digital biomarker)</measure>
    <time_frame>Change from baseline to month 6</time_frame>
    <description>Measured by the number of days a subject uses their electronic pillbox, and for those days it is used, the difference between a given target time and the actual time the pillbox is opened.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Analysis. Intervention Efficacy for Maintenance Dose: Medication adherence measured by electronic pill box (digital biomarker)</measure>
    <time_frame>Change from baseline to month 12</time_frame>
    <description>Measured by the number of days a subject uses their electronic pillbox, and for those days it is used, the difference between a given target time and the actual time the pillbox is opened.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">186</enrollment>
  <condition>Aging</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Conversational Engagement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants engage in 30-minute face-to-face communications with study staff through internet/webcam 4 times per week for 24 weeks (6 months). Under an exploratory aim, a limited number of participants will be further followed by sustaining dose of 2 times per week of 30 minutes session for additional 24 weeks (6 months). Conversational staff will facilitate content-standardized but naturalistic-style social engagement. Staff and participants will engage in conversation about a wide variety of topics that are culturally and personally relevant and interesting to participants. Each day, participants will be able to choose from topic options. Participants will also receive a phone call once per week that lasts approximately 10 minutes; interviewers ask brief questions to monitor participant social activities and health conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will receive a phone call once per week that lasts approximately 10 minutes; interviewers ask brief questions to monitor participant social activities and health conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Conversational Engagement</intervention_name>
    <description>Examine whether increasing social interaction through face-to-face (video chat) conversations could improve cognitive function and whether the efficacy is mediated by improved psychological well-being, targeting older adults aged 75 and older who are socially isolated</description>
    <arm_group_label>Conversational Engagement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 75 or older&#xD;
&#xD;
          2. Consent to MRI (if physically able to receive one)&#xD;
&#xD;
          3. Socially isolated, defined by at least one of the following:&#xD;
&#xD;
             i. Score â‰¤12 on the 6-item Lubben Social Network Scale (LSNS-6), ii. Engages in&#xD;
             conversations lasting 30 minutes or longer no more than twice per week, per subject&#xD;
             self-report iii. Answers &quot;Often&quot; to at least one question on the Hughes et al.&#xD;
             Three-Item Loneliness Scale&#xD;
&#xD;
          4. Adequate vision to use study technology and complete all neuropsychological tests&#xD;
             throughout the study, defined by the following two criteria:&#xD;
&#xD;
             i. See well enough to complete the MoCA ii. See well enough to read a newspaper,&#xD;
             wearing glasses if needed but not using a magnifying glass&#xD;
&#xD;
          5. Adequate hearing to use study technology and complete all neuropsychological tests&#xD;
             throughout the study, defined as i. Able to hear well enough to complete the telephone&#xD;
             screening ii. Able to hear well enough to complete the MoCA&#xD;
&#xD;
          6. Sufficient ability to understand English in order to complete protocol-required&#xD;
             testing&#xD;
&#xD;
          7. Normal cognition or mild cognitive impairment (MCI), as assessed by the trial&#xD;
             neuropsychologist&#xD;
&#xD;
          8. Sufficiently able to comply with protocol assessments and procedures, in the opinion&#xD;
             of the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Identified as having dementia based on either of the following criteria:&#xD;
&#xD;
             i. Self-reported diseases associated with dementia, such as Alzheimer's disease,&#xD;
             vascular dementia, Lewy body dementia, front temporal dementia, normal pressure&#xD;
             hydrocephalus, or Parkinson's disease ii. Diagnosis of dementia by trial&#xD;
             neuropsychologist&#xD;
&#xD;
          2. Anticipating major change in living arrangement within the upcoming year&#xD;
&#xD;
          3. Severely depressed, operationally defined as a 15-item GDS score &gt; 7&#xD;
&#xD;
          4. Significant disease of the central nervous system, such as brain tumor, seizure&#xD;
             disorder, subdural hematoma, or significant stroke, per subject report&#xD;
&#xD;
          5. Current (within 2 years of screening) alcohol or substance abuse&#xD;
&#xD;
          6. Unstable or significantly symptomatic psychiatric disorder, such as major depression,&#xD;
             schizophrenia, posttraumatic stress disorder, or bipolar disorder&#xD;
&#xD;
          7. Unstable or significantly symptomatic cardiovascular disease, such as coronary artery&#xD;
             disease with frequent angina, or congestive heart failure with shortness of breath at&#xD;
             rest&#xD;
&#xD;
          8. Unstable insulin-dependent diabetes mellitus, defined as meeting any of the following&#xD;
             criteria:&#xD;
&#xD;
             i. Received a diagnosis of Type 1 Diabetes ii. Started taking insulin within 3 months&#xD;
             of the screening visit iii. Been hospitalized for hypoglycemia within one year of&#xD;
             screening&#xD;
&#xD;
          9. Active systemic cancer within 5 years of the screening visit (Gleason Grade &lt; 3&#xD;
             prostate cancer and non-metastatic skin cancers are acceptable)&#xD;
&#xD;
         10. Surgery that required full sedation with intubation within 6 months of screening&#xD;
             (sedation for minor procedures is acceptable)&#xD;
&#xD;
         11. More than one overnight hospital stay within 3 months of the screening visit&#xD;
&#xD;
         12. Any other condition that, in the opinion of the investigator, is severe enough to&#xD;
             cause study participation to have a negative impact on participant or study team&#xD;
             rights or wellbeing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroko Dodge, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science Univeristy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.i-conect.org</url>
    <description>Study Website</description>
  </link>
  <reference>
    <citation>Dodge HH, Zhu J, Mattek N, Bowman M, Ybarra O, Wild K, Loewenstein DA, Kaye JA. Web-enabled Conversational Interactions as a Means to Improve Cognitive Functions: Results of a 6-Week Randomized Controlled Trial. Alzheimers Dement (N Y). 2015 May;1(1):1-12.</citation>
    <PMID>26203461</PMID>
  </reference>
  <reference>
    <citation>Dodge HH, Katsumata Y, Zhu J, Mattek N, Bowman M, Gregor M, Wild K, Kaye JA. Characteristics associated with willingness to participate in a randomized controlled behavioral clinical trial using home-based personal computers and a webcam. Trials. 2014 Dec 23;15:508. doi: 10.1186/1745-6215-15-508.</citation>
    <PMID>25539637</PMID>
  </reference>
  <reference>
    <citation>Asgari M, Kaye J, Dodge H. Predicting mild cognitive impairment from spontaneous spoken utterances. Alzheimers Dement (N Y). 2017 Feb 27;3(2):219-228. doi: 10.1016/j.trci.2017.01.006. eCollection 2017 Jun.</citation>
    <PMID>29067328</PMID>
  </reference>
  <reference>
    <citation>Tang F, Uchendu I, Wang F, Dodge HH, Zhou J. Scalable diagnostic screening of mild cognitive impairment using AI dialogue agent. Sci Rep. 2020 Mar 31;10(1):5732. doi: 10.1038/s41598-020-61994-0.</citation>
    <PMID>32235884</PMID>
  </reference>
  <reference>
    <citation>Cerino ES, Hooker K, Goodrich E, Dodge HH. Personality Moderates Intervention Effects on Cognitive Function: A 6-Week Conversation-Based Intervention. Gerontologist. 2020 Jul 15;60(5):958-967. doi: 10.1093/geront/gnz063.</citation>
    <PMID>31112605</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 8, 2016</study_first_submitted>
  <study_first_submitted_qc>August 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Hiroko H. Dodge</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Behavioral intervention</keyword>
  <keyword>social interaction</keyword>
  <keyword>social isolation</keyword>
  <keyword>loneliness</keyword>
  <keyword>dementia, cognitive decline</keyword>
  <keyword>MRI/fMRI</keyword>
  <keyword>objective IADL assessment</keyword>
  <keyword>speech characteristics (acoustic and linguistic)</keyword>
  <keyword>emotional well-being</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All de-identified subject data will stored in a data repository at the conclusion of the research, and made available to approved investigators per a repository protocol.</ipd_description>
    <ipd_time_frame>Data will be available once main trial analyses have concluded, and will be available indefinitely.</ipd_time_frame>
    <ipd_access_criteria>Investigators may access trial data via a repository data sharing request process. Data access will be granted to achieve the aims as outlined in approved data requests. IRB approval may be required.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

